History

vasopharm was founded in July 1998 as a spin-off from the University of Würzburg Medical School by Harald Schmidt, MD, PhD, Professor of Pharmacology and Toxicology, and Ulrich Walter, MD, Professor of Clinical Biochemistry and Pathobiochemistry.

July 1998
Foundation of vasopharm; Business Model: Fee for Service for the pharmaceutical industry until end of 2000

August 2001
Series A Financing round with 3i Group Investments LP as Lead Investor (EUR 6.5 m)

October 2002
License Agreement with BioCytex, Marseille (Cytometric VASP Assay for Clopidogrel® monitoring)

March 2003
Start of GMP production of VAS203

February 2004
Grant of the Bavarian Research Foundation for Nox inhibitors

October 2004
Patent license agreement with Pfizer Inc., USA

November 2004
New investor Entrepreneurs Fund B.V., Amsterdam

September 2005
CE Mark certification for the cytromentric VASP assay

January 2006
Series B Financing round with EMBL Ventures as Lead Investor (EUR 9.7 m)

September 2006
European Commission Grants Orphan Medicinal Product Designation for vasopharm's drug candidate VAS203

December 2006
First human study with vasopharm's trauma compound VAS203

July 2007
Successful completion of first-in-man study with vasopharm's compound VAS203